COURTESY OF THAT STELLAR PIPELINE -BWAHAHAHAHAHAHA DOOSHBAGZ !!!
CEDAR KNOLLS, N.J., Dec 14, 2011 (GlobeNewswire via COMTEX) -- Emisphere Technologies, Inc. (otcqb:EMIS) ("Emisphere" or the "Company") announced today that Novartis Pharma AG ("Novartis") has informed the Company that it will not pursue further clinical development of the investigational drug SMC021 (oral calcitonin) being studied by Nordic Bioscience (the exclusive license partner of Novartis) as a treatment option in two indications, osteoarthritis (OA) and for post-menopausal osteoporosis (OP) and that it will not seek regulatory submission for SMC021 in OA or OP indications.
Novartis advised the Company that its decision to stop the clinical program of SMC021 in both indications was based on analysis and evaluation of data from three Phase III clinical trials (two in OA and one in OP) that showed that while SMC021 displayed a favorable safety profile, it failed to meet key efficacy endpoints in all three trials.
CEDAR KNOLLS, N.J., Dec 14, 2011 (GlobeNewswire via COMTEX) -- Emisphere Technologies, Inc. (otcqb:EMIS) ("Emisphere" or the "Company") announced today that Novartis Pharma AG ("Novartis") has informed the Company that it will not pursue further clinical development of the investigational drug SMC021 (oral calcitonin) being studied by Nordic Bioscience (the exclusive license partner of Novartis) as a treatment option in two indications, osteoarthritis (OA) and for post-menopausal osteoporosis (OP) and that it will not seek regulatory submission for SMC021 in OA or OP indications.
Novartis advised the Company that its decision to stop the clinical program of SMC021 in both indications was based on analysis and evaluation of data from three Phase III clinical trials (two in OA and one in OP) that showed that while SMC021 displayed a favorable safety profile, it failed to meet key efficacy endpoints in all three trials.